Authors


Soliant Health

Latest:

My Healthcare's Better Than Your Healthcare

Long before the current debate on health care started, there was a different war brewing. For decades, people have been fighting over which program and plan is best: healthcare provided to government workers, military personnel or civilians?


Ana Nicholls

Latest:

Patent Filing to Drug Approval: A Difficult Journey Even for the Mighty

The UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years.


Mark McAndrew

Latest:

Co-Pay Offset Programs and the New Health Insurance Marketplace: Will the Feds Say No?

As the health insurance marketplaces begin enrollment this week and go live on January 1, 2014, several issues continue to be a source of significant confusion to manufacturers, payers and the millions of consumers purchasing health insurance for the first time through an exchange.


James Robinson

Latest:

Pricing Management: It's All About the Data

Any pricing or revenue management initiative is only as good as the information on which it is based.


Joe DiMasi

Latest:

Talkback from Tufts: Defending R&D Costs

William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.


Sven Awege

Latest:

Why Don't Those Damn Marketers 'Do' Digital?

Over the last few years I’ve worked with pharma marketers trying to preach and teach the virtues of digital channels. It has been a thankless task, with bucket loads of blood, sweat, and tears of frustration.


Susan Crowley

Latest:

World Health Assembly Underlines Pharma's Global Challenges

Susan Crowley reviews the hotly debated agenda items from last month's World Health Assembly (WHA) in Geneva, Switzerland.


PharmExec Staff

Latest:

Johnson & Johnson, Sanofi Top the 2017 Good Pharma Scorecard

The 2017 GPS ranking evaluates clinical trial registration, results reporting, clinical study report synopsis sharing, and journal article publication rates for new drugs approved by the Food and Drug Administration in 2014 that were sponsored by large drug companies.


Pamela Walker, Ph.D

Latest:

ESG: Applying Lessons From Consumer Market

A prime opportunity for pharma to raise its strategic game in ESG.


Jacob Snapp

Latest:

Supply Chain Analytics: Pharma’s Next Big Bet

Examining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.


Srihari Rangarajan

Latest:

Supply Chain Analytics: Pharma’s Next Big Bet

Examining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.


Jesper Hoiland

Latest:

Beyond the Blame Game: How Pharma is Learning to Collaborate

In a follow-up to our November CEO profile, Novo Nordisk’s Jesper Høiland writes how pharma companies and insurers are learning to collaborate.


Daryl Travis

Latest:

Marketing: Beware the Hidden Forces of Behavioral Economics

Brand success can hinge on discovering the deeper motivations of customers and addressing the cognitive biases that result.



Christopher-Paul Milne

Latest:

FDA’s Breakthrough Therapy Designation

Three key questions dominate the agency’s Breakthrough Therapy Designation program since its 2012 launch.


Keith Fern

Latest:

Community Clinics as Trial Sites—Bridging the Gap Between Healthcare and Clinical Research

Keith Fern looks at how community clinics can be turned into research sites.


Rick Lynch

Latest:

Nine Pharma Lessons from the Battlefield

Rick Lynch, the Army General who led the Iraqi ‘surge’ campaign, cites nine lessons that pharma leaders can apply in today’s come-from-behind struggle for market share.


Michael Jaeger

Latest:

Withdrawal of EU Investigation of the Patent Box: Good News for UK Innovators

The European Commission’s (EC) decision to withdraw its investigation into the UK Government's Patent Box scheme is positive news for British innovators, writes Michael Jaeger.


Susan McDonald

Latest:

The End of Pharma Marketing— or a New Beginning?

Two commercial marketing experts discuss how this mission critical function must change to stay relevant in bringing new therapies to the patients who need them.


Sanjiv Sharma

Latest:

Case Study: A Drug Launch into COVID Headwinds

Lessons to launch by during a pandemic—or otherwise.


Donna Vetter

Latest:

Biosimilars: Finding the Right Path to Differentiation

How will companies market similarity in a way that differentiates from the innovator? Customer experience may be the key.


Ed Schoonveld

Latest:

Philanthropy vs. Innovation - Current Vaccine Prices: Is There a Downside?

Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.



Mike Straw

Latest:

Pharma Boards in the Era of Hostile Takeovers

With hostile takeovers on the rise, Mike Straw argues that pharma boards have a huge role to play in managing the people issues.


Mark Gross

Latest:

Prastera: A Drug Listing Submission Case Study

Mark Gross offers a case study in using structured product labeling (SPL) to reduce time to market.


Timothy White

Latest:

Pharma's Love Affair with Buzzwords

How pharma can finally put true meaning behind its juiced-up jargon and turn the bluster into reality, by Lundbeck's Timothy White.


Rolf Fricker

Latest:

Tomorrow’s Selling Strategies: Invest & Test

A new PwC survey reveals a strong need to fully embrace alternative commercial methods-not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.


Rick Edmunds

Latest:

Value-Based Planning Uncovers True Drivers of Cost Across Life Sciences Organizations

Explicitly tying strategic planning to resource allocation boosts bottom-line productivity for pharma.


Nelia Padilla

Latest:

Tomorrow’s Selling Strategies: Invest & Test

A new PwC survey reveals a strong need to fully embrace alternative commercial methods-not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.


Chai Hoang and Chris Bard

Latest:

Refuting R&D Tax Credit Myths

Why executives should make the US R&D tax credit part of their planning discussions, by Chai Hoang and Chris Bard.